Wyva
Senior Member (Voting Rights)
Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers — An updated European Academy of Neurology consensus statement
Saša R. Filipović, Serefnur Özturk, Daniel Bereczki, Benedetta Bodini, Francesco Cavallieri, Alessandra Fanciulli, Alla Guekht, Raimund Helbok, Sonja Hochmeister, Filippo Martinelli Boneschi, Alberto Priori, Martin Rakusa, Michele Romoli, Barbara Willekens, Marialuisa Zedde, Johann Sellner,
Johann Sellner, Elena Moro, for the Neuro COVID-19 Task Force of the European Academy of Neurology
Abstract
Background and purpose
In October 2020, the European Academy of Neurology (EAN) consensus statement for management of patients with neurological diseases during the coronavirus disease 2019 (COVID-19) pandemic was published. Due to important changes and developments that have happened since then, the need has arisen to critically reassess the original recommendations and address new challenges.
Methods
In step 1, the original items were critically reviewed by the EAN COVID-19 Task Force. In addition, new recommendations were defined. In step 2, an online survey with the recommendations forged in step 1 was sent to the Managing Groups of all Scientific and Coordinating Panels of EAN. In step 3, the final set of recommendations was made.
Results
In step 1, out of the original 36 recommendations, 18 were judged still relevant. They were edited to reflect the advances in knowledge and practice. In addition, 21 new recommendations were formulated to address the new knowledge and challenges. In step 2, out of the 39 recommendations sent for the survey, nine were approved as they were, whilst suggestions for improvement were given for the rest. In step 3, the recommendations were further edited, and some new items were formed to accommodate the participants' suggestions, resulting in a final set of 41 recommendations.
Conclusion
This revision of the 2020 EAN Statement provides updated comprehensive and structured guidance on good clinical practice in people with neurological disease faced with SARS-CoV-2 infection. It now covers the issues from the more recent domains of COVID-19-related care, vaccine complications and post-COVID-19 conditions.
Open access: https://onlinelibrary.wiley.com/doi/10.1111/ene.16408
Saša R. Filipović, Serefnur Özturk, Daniel Bereczki, Benedetta Bodini, Francesco Cavallieri, Alessandra Fanciulli, Alla Guekht, Raimund Helbok, Sonja Hochmeister, Filippo Martinelli Boneschi, Alberto Priori, Martin Rakusa, Michele Romoli, Barbara Willekens, Marialuisa Zedde, Johann Sellner,
Johann Sellner, Elena Moro, for the Neuro COVID-19 Task Force of the European Academy of Neurology
Abstract
Background and purpose
In October 2020, the European Academy of Neurology (EAN) consensus statement for management of patients with neurological diseases during the coronavirus disease 2019 (COVID-19) pandemic was published. Due to important changes and developments that have happened since then, the need has arisen to critically reassess the original recommendations and address new challenges.
Methods
In step 1, the original items were critically reviewed by the EAN COVID-19 Task Force. In addition, new recommendations were defined. In step 2, an online survey with the recommendations forged in step 1 was sent to the Managing Groups of all Scientific and Coordinating Panels of EAN. In step 3, the final set of recommendations was made.
Results
In step 1, out of the original 36 recommendations, 18 were judged still relevant. They were edited to reflect the advances in knowledge and practice. In addition, 21 new recommendations were formulated to address the new knowledge and challenges. In step 2, out of the 39 recommendations sent for the survey, nine were approved as they were, whilst suggestions for improvement were given for the rest. In step 3, the recommendations were further edited, and some new items were formed to accommodate the participants' suggestions, resulting in a final set of 41 recommendations.
Conclusion
This revision of the 2020 EAN Statement provides updated comprehensive and structured guidance on good clinical practice in people with neurological disease faced with SARS-CoV-2 infection. It now covers the issues from the more recent domains of COVID-19-related care, vaccine complications and post-COVID-19 conditions.
Open access: https://onlinelibrary.wiley.com/doi/10.1111/ene.16408